Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2011 3
2012 1
2014 2
2016 3
2017 3
2018 2
2019 4
2020 4
2021 7
2022 7
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Among authors: pethe a. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
Polymers, responsiveness and cancer therapy.
Pethe AM, Yadav KS. Pethe AM, et al. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):395-405. doi: 10.1080/21691401.2018.1559176. Artif Cells Nanomed Biotechnol. 2019. PMID: 30688110 Review.
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P. van Zyl-Smit RN, et al. Among authors: pethe a. J Asthma Allergy. 2023 Jan 20;16:123-134. doi: 10.2147/JAA.S392975. eCollection 2023. J Asthma Allergy. 2023. PMID: 36714049 Free PMC article. Review.
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC. Brittain D, et al. Among authors: pethe a. Adv Ther. 2022 Jun;39(6):2365-2378. doi: 10.1007/s12325-021-02025-w. Epub 2022 Jan 24. Adv Ther. 2022. PMID: 35072888 Free PMC article. Review.
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Chapman K, van Zyl-Smit R, Maspero J, Kerstjens HAM, Gon Y, Hosoe M, Tanase AM, Pethe A, Shu X, D'Andrea P. Chapman K, et al. Among authors: pethe a. BMJ Open Respir Res. 2021 Aug;8(1):e000819. doi: 10.1136/bmjresp-2020-000819. BMJ Open Respir Res. 2021. PMID: 34452934 Free PMC article.
44 results